Equity Overview
Price & Market Data
Price: $0.724
Daily Change: +$0.0128 / 1.77%
Daily Range: $0.695 - $0.74
Market Cap: $44,077,024
Daily Volume: 48,315
Performance Metrics
1 Week: 14.27%
1 Month: 20.82%
3 Months: 70.30%
6 Months: 13.22%
1 Year: -2.42%
YTD: 1.38%
Company Details
Employees: 28
Sector: Health technology
Industry: Biotechnology
Country:
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.